THAR: Rasio kapitalisasi pasar marang pendapatan Tharimmune Inc

Successes in the development of the TH104 antibody and patent potential are driving the creation of unique biologics, which is reflected in the historical P/S of Tharimmune, Inc. (THAR) on GURU.Markets through valuation dynamics, where the value indicates the current magnitude. The picture is completed by strict control of pharmaceutical logistics, guaranteeing patient safety and the precision of clinical trials in oncology.

The P/S ratio reflects the market value of one dollar of revenue, correlating market capitalization with the issuer's actual trading turnover. For Tharimmune, Inc. (THAR), which develops unique antibodies for dermatological and hepatic pathologies, this coefficient measures market expectations regarding the future commercialization of its therapies. By analyzing the business valuation via P/S, an investor determines the extent of the premium paid for innovation potential. This metric allows for an objective comparison of the asset's value against its current operational efficiency.